Compare Ford Motor Company (F) vs Inovio Pharmaceuticals Inc (INO) Price & Performance

Ford (F) trades at $13.93, up 0.44% on the day, with a neutral technical outlook and mixed fundamental signals. The company reported a net loss of $8.18 billion in 2025 despite revenue growth to $187.27 billion, reflecting margin pressure. Recent news highlights labor agreements, EV initiatives, and a 4%+ dividend yield. Analyst consensus is a $15.00 price target with a Hold-heavy rating distribution.

The stock presents a value opportunity with low P/E and P/S ratios, but significant risks include persistent net losses, high debt levels, and competitive pressures in the EV transition. Upside depends on execution of cost controls and successful new product launches, particularly in electric vehicles.

INO trades at $1.16 with no recent price movement, reflecting its speculative biotech profile. The company shows consistent quarterly earnings beats but operates with minimal revenue ($65K in 2025) and significant losses (-$85M net income). Technical indicators are bearish overall, though some oscillators suggest potential oversold conditions. Recent news highlights the critical FDA decision for INO-3107 in October 2026 as the primary near-term catalyst.

The investment case hinges entirely on regulatory approval of INO-3107, with analysts maintaining a cautiously optimistic stance (53% buy ratings). However, substantial financial risks persist including negative cash flow, high burn rate, and shareholder litigation. Successful FDA approval could drive significant upside, while rejection would likely exacerbate financial pressures.